drugset / Trial / NCT02181504
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.
Timeline
- Start
- 2014-09
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abicipar pegol | Protein / enzyme biologic | 1 mg | Intravitreal |
| Subject | Abicipar pegol | Protein / enzyme biologic | 2 mg | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |